Publication | Closed Access

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Sunitinib Versus SunitinibUrologyGenitourinary CancerMedicineMultipeptide Cancer VaccineImmunologyImmune Checkpoint InhibitorCancer TreatmentOncologyTumor MicroenvironmentPhase 3